 | |
| Company type | Public |
|---|---|
| |
| ISIN | DK0015998017 |
| Industry | Biotechnology |
| Founded | 1994 |
| Headquarters | Philip Heymans Alle 3 DK-2900 Hellerup, , Denmark |
Key people | |
| Products | Imvanex, Imvamune, Jynneos, Rabipur/RabAvert, Encepur, Vivotif, Vaxchora, Mvabea |
| Revenue |  7.062 billion kr. (2023) |
| Total assets | 14.373 billion kr. (2023) |
| Total equity | 10.340 billion kr. (2023) |
Number of employees | 1.379 (2023) |
| Website | www.bavarian-nordic.com |
| Footnotes / references [6] | |
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland.[3] The company has research and development facilities in Martinsried, Germany and San Diego, California, as well as offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors and virus-like particles in its research and development.
- ^ "Archive.ph". Archived from the original on 2022-03-13. Retrieved 2023-09-08.
{{cite web}}: CS1 maint: bot: original URL status unknown (link) - ^ "OMX Copenhagen 25 (OMXC25CAP)" (PDF). Nasdaq OMX. Archived from the original (PDF) on 13 March 2022.
- ^ a b "Hellerup, Denmark". Bavarian Nordic. Archived from the original on March 13, 2022. Retrieved 6 December 2021.
- ^ "Board of Directors". BN. Retrieved 2024-04-08.
- ^ "Executive Management". BN. Archived from the original on 2020-07-17. Retrieved 2024-04-08.
- ^ "Annual Report 2023" (PDF). Bavarian Nordic. Archived from the original (PDF) on April 2, 2024. Retrieved April 8, 2024.